Latest News

A revolution in the way that sexual dysfunction is treated could be just around the corner. Bremelanotide (formerly known as PT-141), which forms part of a new class of drugs called melanocortin agonists, is being developed in the United States by Palatin Technolgies. The drug works through a mechanism of actions involving the central nervous system rather than directly on the vascular system like currently available drugs, such as Viagra and Cialis. Given that Bremelanotide works in a completely different way from existing drugs on the market, it is thought that it may be able to be used by patients for whom the current generation of drugs are either contraindicated or are ineffective.

According to market data, around 40% of men who are prescribed the currently available drugs to treat erectile dysfunction do not refill their prescription as a result of a lack of efficacy or intolerable side effects. Palatin therefore believes that there is significant market demand for an alternative form of drug therapy.

Bremelanotide has been shown in four Phase 2 clinical trials to be effective in treating erectile dysfunction and it is currently undergoing Phase 2A clinical trials to treat pre-menopausal women suffering from sexual dysfunction, early results of which are encouraging according to Palatin. The drug is administered by way of a nasal spray and seems to have few side effects which are not dose related.

We will bring you more news on this exciting drug as soon as we have it.